BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 23, 2009
View Archived Issues
Sanofi-aventis scientists describe new anticancer Hsp90 inhibitors in recent patent
Read More
GSK claims novel PI3Kalpha inhibitors with potential as anticancer agents
Read More
BMS scientists report new dual-action NK-1 antagonists/5-HT reuptake inhibitors
Read More
New P2Y12 receptor antagonists claimed by sanofi-aventis for thrombotic disorders
Read More
Kyowa Hakko Kirin reports prostanoid FP receptor agonists with antiglaucoma properties
Read More
New histamine H3 receptor antagonists for treatment of AD reported by Wyeth
Read More
Novel neuraminidase inhibitors for treating influenza prepared at Hokkaido University
Read More
PanThera divulges new anthrax lethal factor inhibitors
Read More
Target candidate: CTGF/CCN2, a protective factor in pancreatic tumor cells
Read More
Biopartners appeal the CHMP's negative opinion on Biferonex
Read More
Endocyte begins phase II EC-145 trial for ovarian cancer
Read More
FDA issues public health advisory for Raptiva, EMEA recommends suspension
Read More
European Commission approves Firmagon for prostate cancer
Read More
EMEA recommends continued vaccination with Gardasil
Read More
CV Therapeutics rejects Astellas Pharma's unsolicited proposal
Read More
Astellas Pharma offers third quarter summary
Read More
Shire acquires worldwide rights to Equasym IR/XL from UCB
Read More
QRxPharma initiates comparative study of MoxDuo in knee replacement surgery
Read More
Schering-Plough submits response to FDA complete response letter for Saphris NDA
Read More
BioInvent and ThromboGenics commence phase II trial of TB-402
Read More
UCB presents outcomes for proof-of-concept lacosamide and rotigotine studies
Read More
Encouraging results support further development of Almirall's LAS-100977
Read More
Acrux reports positive data for contraceptive skin spray trials
Read More